A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

NCT03234712 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Cancer

Interventions

DRUG: ABBV-321

Sponsor

AbbVie